01455nas a2200349   4500000000100000008004100001653002600042653001600068653001200084653003700096653003300133653003100166653003000197653001100227653001100238653002300249653001200272653000900284653002500293653001400318653001300332653002000345653002200365653003000387100001100417700001200428245002600440300001000466490000700476520060800483022001401091       2015                            d10aAnti-Bacterial Agents10aClofazimine10aDapsone10aDose-Response Relationship, Drug10aDrug Administration Schedule10aDrug Resistance, Bacterial10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMycobacterium leprae10aPrognosis10aRifampin10aRisk Assessment10aTreatment Outcome10aWorld Health Organization1 aKar HK1 aGupta R00aTreatment of leprosy.  a55-650 v333 a<p>Leprosy is a curable disease, having been eliminated from many countries, including India. This has been possible due to the wide availability of effective and safe drugs. Treatment of leprosy has undergone considerable changes over decades, from chaulmoogra oil in 1915 to dapsone monotherapy in 1946, then eventually to multidrug therapy (MDT) in 1982. In the last two decades, reports of resistance to all first-line drugs have appeared in the literature, with the need to conduct clinical trials using newer but highly bactericidal drugs and their combinations against Mycobacterium leprae.</p>
  a1879-1131